Exercise 1 (OAI) | Exercise 2 | |||
---|---|---|---|---|
Mean (SD) unless specified | Injection (n=40) | Control (n=40) | All (n=80) | (Adalimumab) All (n=16) |
Age (years) | 62.3 (8.5) | 62.3 (8.6) | 62.3 (8.6) | 57.8 (10.2) |
Males (%) | 8 (20%) | 8 (20%) | 16 (20%) | 7 (35%) |
Symptom duration (years) | NA | NA | NA | 4.7 (4.2) |
WOMAC pain (max. 20) | 5.0 (3.5) | 3.2 (3.9) | 4.1 (3.8) | 11.9 (3.5) |
WOMAC function (max. 68) | 24.8 (16.6) | 15.6 (17.3) | 20.2 (17.5) | 43.6 (12.4) |
Kellgren-Lawrence Grade | 2.9 (1.1) | 2.8 (1.1) | 2.9 (1.1) | 2.8 (0.4) |
K-L grade 0: n (%) | 1 (2.5%) | 1 (2.5%) | 2 (2.5%) | 0 (0%) |
K-L grade 1: n (%) | 5 (12.5%) | 5 (12.5%) | 10 (12.5%) | 0 (0%) |
K-L grade 2: n (%) | 6 (15%) | 6 (15%) | 12 (15%) | 4 (25%) |
K-L grade 3: n (%) | 16 (40%) | 16 (40%) | 32 (40%) | 12 (75%) |
K-L grade 4: n (%) | 12 (30%) | 12 (30%) | 24 (30%) | 0 (0%) |
Max., maximum; NA, not available; OAI, Osteoarthritis Initiative; WOMAC, Western Ontario and McMaster Universities.